Change to lipid modification guideline CG67
Changes have been made to the guideline on Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG67). The changes relate to recommendations on methods of cardiovascular risk estimation.
NICE was aware when the guideline was published in May 2008 that the evidence on cardiovascular risk estimation was developing rapidly. In view of the publication in 2009 of more evidence comparing QRISK with other risk estimation tools, the Institute's Centre for Clinical Practice sought a view from members of the original guideline development group on whether the new evidence warranted an update of the guideline at this stage. There was no consensus among the members of the group that there was sufficient new evidence to allow for a clear decision in recommending one cardiovascular risk estimation method over another.
NICE's Guidance Executive considered this feedback and came to the view that, although the evidence has moved on, an update was not appropriate as it did not seem that a clear conclusion would be reached favouring one method over another. In these circumstances the decision was taken to withdraw the guidance relating to a particular method of estimation so that the decision could be left to the NHS locally to use the method best suited to their requirements.
The amended versions of the guideline are available here.
25 March 2010
This page was last updated: 17 April 20402040